Business
Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today published the invitation to the Annual General Meeting 2026 and announced the nomination of Clare Fisher for election as a new member of the Board of Directors (BoD) at the Annual General Meeting. The A
About this update from Molecular Partners Ag
[{"type":"image","alt":"Molecular Partners","displaySize":"","headline":null,"caption":"Molecular Partners","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/81b364e4c3e34884b6ba113a6f539ffa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BGDE_l77THUOG4fn3eDz8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk4/https://media.zenfs.com/en/globenewswire.com/81b364e4c3e34884b6ba113a6f539ffa","width":300,"height":70}},"lazy":false},{"type":"text","content":"ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today published the invitation to the Annual General Meeting 2026 and announced the nomination of Clare Fisher for election as a new member of the Board of Directors (BoD) at the Annual General Meeting.","length":494,"tagName":"p"},{"type":"text","content":"The Annual General Meeting will be held on Tuesday, April 14, 2026, 9:00 am CET (doors open at 8:30 am CET), at JED Events, Zürcherstrasse 39, 8952 Schlieren, Switzerland.","length":171,"tagName":"p"},{"type":"text","content":"Invitation to the Annual General Meeting 2026 with the corresponding agenda items.","length":82,"tagName":"p"},{"type":"text","content":"Einladung zur Generalversammlung 2026 mit den zugehörigen Traktandenpunkten.","length":76,"tagName":"p"},{"type":"text","content":"“We are pleased to propose Clare Fisher for election to our BoD. Clare brings extensive leadership experience in business and corporate development in the biotech and pharmaceutical industry, and we believe her strategic and hands-on skillsets will be valuable for our partnerships and for our growing pipeline of innovative therapeutics,” said Bill Burns, Chairman of the Board of Directors of Molecular Partners.","length":414,"tagName":"p"},{"type":"text","content":"Clare Fisher is currently the SVP for Global Business Development and M&A at BeOne Medicines, global oncology company committed to discovering and developing innovative treatments for cancer patients worldwide. Clare has more than two decades of healthcare experience in leadership roles, including corporate and business development, me...